NIRV — Nirvana Life Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$5.06m
- CA$5.16m
Annual income statement for Nirvana Life Sciences, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 6 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.314 | 0.334 | 5.35 | 1.49 | 0.873 |
| Operating Profit | -0.314 | -0.334 | -5.35 | -1.49 | -0.873 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.314 | -0.254 | -5.66 | -1.49 | -0.873 |
| Net Income After Taxes | -0.314 | -0.254 | -5.66 | -1.49 | -0.873 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.314 | -0.254 | -5.65 | -1.49 | -0.872 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.314 | -0.254 | -5.65 | -1.49 | -0.872 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.044 | -0.036 | -0.032 | -0.037 | -0.016 |
| Dividends per Share |